Please note that the application period has closed for 2021 and will reopen again in 2023.


All grant proposals should be submitted online through the Gilead Grant Portal tagging ALL4LIVER Grant Program and should specify the focus area the proposal falls under.


The applications will be reviewed by an advisory panel made up of experts from across the Asia Pacific region who are leaders in liver disease research, public health knowledge or patient advocacy work. Upon recommendation of the advisory panel, a Gilead grant review committee will make the final decision on which of the proposals to award grants.

Application Process

Grant application period has closed for 2021
Announcement of 2021 grantees

Early 2022

Grant application opens

Early 2023

Focus Area


Strengthen peer support

Patient/peer support groups are traditionally identified as important groups for education and awareness. The grant aims to strengthen and enhance patient support services and encourage peer support to link patients and those at-risk to screening and care​.


Improve hepatitis B awareness and literacy

Understanding of hepatitis B, screening and intervention options can ultimately improve disease management. Increasing awareness and in-depth understanding of hepatitis B can also help to eliminate stigma and discrimination related to hepatitis B.



As consumers’ information-seeking behaviors are evolving, the grant seeks innovative approaches to increase disease awareness outside of clinical settings.

Eligibility Criteria

We welcome proposals from groups that meet the following criteria:

Certification of non-profit tax status through an official or government-issued document (including academic institution)

Established for at least two years at the time of the grant application, with strong track record of program execution ​

Sound financial stewardship, strong commitment to good corporate governance, compliance, and ethics​

Demonstrate understanding of viral hepatitis especially HBV, and the at risk communities (including those with other disease groups such as liver cancer, HCV, HIV)​

Located in at least one of the following territories: Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam

Funding Guidance:

Costs for screening or purchase of equipment for screening are not covered by the Grant. For projects that involve screening in their service model, applicant is recommended to partner with a third party or seek third party funds to cover the cost of screening

Maximum grant amount of US$150,000 will be set for each project idea, regardless of cost of project implementation across countries and territories, medium chosen, project duration

May team up with other groups for the execution of the project but funds will only be granted to one group as project coordinator

The selected project is required to conclude within 18 months after execution of the agreement (Feb 2022 to Jul 2023)


All grant proposals must be submitted online through the Gilead grant portal

Submissions need to be completed in English; applicants who need support on language matters before submitting their proposal can email

Please tag Gilead ALL4LIVER Grant Program and specify which focus area the proposal falls under

#These are general guiding principles. There may be additional eligibility requirement based on individual countries’ local laws and regulations.

Advisory Panel

Our gratitude to the following experts for being advisors of the 2021 program
(in alphabetical order):

Chan Stephen L.

Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong

Tan Chee Kiat

Senior Consultant, Gastroenterology & Hepatology, Singapore General Hospital, Singapore

Tanwandee Tawesak

Head, Division of Gastroenterology Department of Medicine, Mahidol University, Thailand

Khwairakpam Giten

Program Manager, TREAT Asia/ amfAR, Thailand

Yang Hwai-I

Deputy Director, Genomics Research Center, Academia Sinica, Taiwan

Lee Myoung-Ah

Professor, Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, South Korea

Yim Hyung Joon

Professor, Division of Gastroenterology and Hepatology, Korea University Ansan Hospital, South Korea

Shanmugam Rengasamy Ponnusamy

Executive Board Member, South-East Asia, World Hepatitis Alliance

Yuen Man-Fung

Professor, Chief of Division of Gastroenterology and Hepatology, University of Hong Kong, Hong Kong

Su Tung-Hung

Clinical Associate Professor, Division of Gastroenterology, National Taiwan University Hospital, Taiwan